23:35 , Aug 22, 2018 |  BC Innovations  |  Translation in Brief

Confirming CRISPR

Two critiques of a 2017 human embryo gene editing study, including one suggesting large deletions at the target site misled researchers into thinking CRISPR-Cas9 corrected a genetic mutation, raise questions about what assays and screening...
16:04 , Jul 16, 2018 |  BC Extra  |  Preclinical News

On-target mutations latest worry for CRISPR stocks

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology....
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five...
19:31 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

FDA clears Amicus to submit migalastat NDA without new trial

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) said FDA would no longer require an additional Phase III study of migalastat (AT1001) to treat Fabry's disease, clearing the way for the company to submit an NDA...
00:08 , Jul 12, 2017 |  BC Extra  |  Company News

FDA clears Amicus to submit migalastat NDA without new trial

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) gained $2.66 (26%) to $12.92 on Tuesday after it said FDA would no longer require an additional Phase III study of migalastat ( AT1001 ) to treat Fabry's...
21:45 , Dec 9, 2016 |  BioCentury  |  Finance

Networking for cash

After raising its first two rounds from philanthropic investors and large Western institutional funds, antibody platform company Kymab Group Ltd. has leveraged its broad network in Asia into the largest U.K. venture financing of the...
07:00 , Aug 11, 2016 |  BC Innovations  |  Targets & Mechanisms

Niche for the aged

A pair of Nature Medicine studies has placed integrin β1 signaling at the center of post-injury muscle regeneration in elderly patients. With one study pointing to the receptor and the other to its ligand, the...
07:00 , Jul 19, 2016 |  BC Extra  |  Financial News

Third Rock backs Fulcrum in $55M series A

Third Rock Ventures launched Fulcrum Therapeutics Inc. (Cambridge, Mass.) and was the sole investor in the gene control company's $55 million series A financing. Fulcrum is developing small molecules that modulate targets responsible for regulating...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: P selectin glycoprotein ligand-1 (PSGL-1; CD162; SELPLG)

Infectious disease INDICATION: Viral infection; melanoma Mouse studies suggest PSGL-1 inhibitors could help treat chronic viral infections or melanoma. In a mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection, knockout of PSGL-1 decreased viral...